FDA’s Testosterone Label Changes
This Perspective discusses US Food and Drug Administration (FDA) updates to testosterone product labeling and their implications for prescribing practice.
Authors
- Alvin M. Matsumoto (ORCID: https://orcid.org/0000-0002-6506-8650)
- Richard Joseph Auchus (ORCID: https://orcid.org/0000-0001-6815-6181)
- Shalender Bhasin M. D (ORCID: https://orcid.org/0000-0002-3982-6200)
Institutions
- Brigham and Women's Hospital (US)
- University of Washington (US)
- University of Michigan (US)
- VA Puget Sound Health Care System (US)
- Michigan Medicine (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-10-15
- DOI
- https://doi.org/10.1001/jama.2026.18140
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00